BRCA2 Pancreatic Cancer — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — TA750 was terminated without a NICE recommendation for pancreatic olaparib
Explanation lettering: E = shown as A · C = shown as B · A = shown as C · B = shown as D · D = shown as E
D is correct and separates trial evidence from national commissioning guidance. A mistakes publication for appraisal; B broadens both biomarker and funding criteria; C transfers a technology appraisal across indications; E reverses the maintenance population and invents a funding position.
Reference: NICE TA750 olaparib for metastatic pancreatic cancer: terminated appraisal (Published 1 December 2021; current NICE position): https://www.nice.org.uk/guidance/ta750